博瑞医药表示，截至9月24日，公司收盘价为72.5元/股。根据中证指数有限公司发布的数据，截至9月 23日，公司最新滚动市盈率为313.01倍，公司所处的医药制造业最近一个月平均滚动市盈率为31.43倍， 公司市盈率显著高于行业市盈率水平。 北京商报讯(记者丁宁)9月24日晚间，博瑞医药(688166)发布公告称，公司股票连续30个交易日内收盘价 格跌幅偏离值累计达到70%，根据《上海证券交易所交易规则》《上海证券交易所科创板股票异常交易 实时监控细则》的有关规定，属于股票交易严重异常波动情形。 博瑞医药还表示，经公司自查，公司目前日常经营情况正常，未发生重大变化。市场环境或行业政策未 发生重大调整，生产成本和销售等情况未出现大幅波动，内部生产经营秩序正常。 ...

证券代码：688166 证券简称：博瑞医药 公告编号：2025-065 博瑞生物医药（苏州）股份有限公司 股票交易严重异常波动公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 博瑞生物医药（苏州）股份有限公司（以下简称"公司"）股票连续 30 个交易日内收盘价格跌幅偏离值累计达到 70%，根据《上海证券交易所交易规则》 《上海证券交易所科创板股票异常交易实时监控细则》的有关规定，属于股票交 易严重异常波动情形。 经公司自查并发函向控股股东及实际控制人核实，截至本公告披露日， 公司不存在应披露而未披露的重大事项。 截至 2025 年 9 月 24 日，公司收盘价为 72.50 元/股。根据中证指数有限 公司发布的数据，截至 2025 年 9 月 23 日，公司最新滚动市盈率为 313.01 倍， 公司所处的医药制造业最近一个月平均滚动市盈率为 31.43 倍，公司市盈率显著 高于行业市盈率水平。公司特别提醒广大投资者，注意投资风险，理性决策，审 慎投资。 一、股票交易严重异常波动的具体情况 公司股票连续 ...

Core Insights - On September 24, a total of 31 stocks were identified with institutional activity, with 17 showing net buying and 14 showing net selling [1] Institutional Buying - The top three stocks with the highest net institutional buying were Huicheng Co., Beifang Huachuang, and Lixing Co., with net buying amounts of 152 million, 143 million, and 138 million respectively [1] Institutional Selling - The top three stocks with the highest net institutional selling were Borui Pharmaceutical, Changchuan Technology, and Kaimete Gas, with net outflow amounts of 471 million, 348 million, and 131 million respectively [1]

博瑞医药晚间公告，公司股票连续30个交易日内收盘价格跌幅偏离值累计达到70%，根据《上海证券交 易所交易规则》《上海证券交易所科创板股票异常交易实时监控细则》的有关规定，属于股票交易严重 异常波动情形。经公司自查，公司目前日常经营情况正常，未发生重大变化。市场环境或行业政策未发 生重大调整，生产成本和销售等情况未出现大幅波动，内部生产经营秩序正常。 ...

博瑞医药公告，公司股票连续30个交易日内收盘价格跌幅偏离值累计达到70%，根据《上海证券交易所 交易规则》《上海证券交易所科创板股票异常交易实时监控细则》的有关规定，属于股票交易严重异常 波动情形。经公司自查，公司目前日常经营情况正常，未发生重大变化。市场环境或行业政策未发生重 大调整，生产成本和销售等情况未出现大幅波动，内部生产经营秩序正常。 ...

共31只个股出现了机构的身影。 盘后数据显示，9月24日龙虎榜中，共31只个股出现了机构的身影，有17只股票呈现机构净买入，14只 股票呈现机构净卖出。 当天机构净买入前三的股票分别是汇成股份、北方华创、力星股份，净买入金额分别是1.52亿元、1.43 亿元、1.38亿元。 当天机构净卖出前三的股票分别是博瑞医药、长川科技、凯美特气，净流出金额分别是4.71亿元、3.48 亿元、1.31亿元。 | IN FE A FENDE | 一 机构资金参与个股 | | | --- | --- | --- | | 证券简称 | 冒涨跌幅 | 机构净买入(万元) | | 汇成股份 | 15.84% | 15173.86 | | 北方华创 | 10.00% | 14288.91 | | 力星股份 | 14.78% | 13840.74 | | 聚辰股份 | 6.93% | 10143.32 | | 北化股份 | 9.98% | 8993.94 | | 矽电股份 | 12.46% | 8425.42 | | 恩捷股份 | 9.99% | 6678.65 | | 和而泰 | 1.47% | 5377.87 | | 唯特偶 | 4 ...

Core Viewpoint - The A-share market is experiencing a significant rebound, particularly in the Sci-Tech Innovation Board, with the ETF Huatai-PineBridge (589120) showing a notable increase of 1.59% as of 13:54 on September 24, and attracting over 20 million yuan in net subscriptions within three trading days [1][3]. Group 1: ETF Performance - The Huatai-PineBridge Sci-Tech Innovation Drug ETF (589120) has seen strong performance, with most of its constituent stocks rising, including Teva Biopharma up over 3%, and several others like Zai Lab and Eucure Biopharma rising over 2% [3]. - The top ten constituent stocks of the ETF include notable companies such as RYSE Pharmaceuticals (688235) with a weight of 9.92% and a rise of 1.93%, and Eucure Biopharma (688578) with a weight of 8.03% and a rise of 2.27% [4]. Group 2: Market Dynamics - The National Healthcare Security Administration is set to hold a communication meeting in Beijing to discuss negotiations and pricing with companies, marking a significant innovation in this year's healthcare directory adjustments [5]. - The current innovation drug market is driven by the trend of "local innovation - global monetization," which is seen as a key support for the industry's growth [6]. - Analysts from Xinda Securities believe that the trend of innovation in the drug sector is not over, with expectations for continued growth in innovative drugs, medical devices, and AI healthcare [7]. Group 3: Industry Outlook - Tianfeng Securities highlights that the Chinese innovative drug industry has achieved significant results and is now globally competitive, entering a phase of self-sustainability through commercialization [8]. - The industry is supported by favorable policies, a well-structured talent pool, and a collaborative approach between academia and industry, which enhances the efficiency of drug development [9]. - The future outlook suggests that increasing innovation will further unlock commercial value, with China becoming one of the most efficient countries in the drug development process [10].

Group 1 - The core point of the news is that Borui Pharmaceutical's stock has experienced a significant decline, dropping 5.27% on September 24, with a cumulative drop of 21.94% over three consecutive days [1][2] - As of the report, Borui Pharmaceutical's stock price is 70.12 yuan per share, with a trading volume of 839 million yuan and a turnover rate of 2.76%, resulting in a total market capitalization of 29.645 billion yuan [1] - Borui Pharmaceutical, established on October 26, 2001, and listed on November 8, 2019, focuses on the research and production of high-end generic drugs and original new drugs [1] Group 2 - Longcheng Fund has a significant holding in Borui Pharmaceutical, with its Longcheng SSE Sci-Tech Innovation Board 100 Index Enhanced A fund holding 28,300 shares, accounting for 1.85% of the fund's net value, making it the ninth-largest holding [2] - The fund has incurred a floating loss of approximately 110,500 yuan today and a total floating loss of 589,500 yuan during the three-day decline [2] - The fund manager, Lei Jun, has been in position for 10 years and 279 days, with the fund's total asset size at 3.443 billion yuan and a best return of 166.88% during his tenure [2]

Group 1 - Pfizer announced a $7.3 billion acquisition of weight loss drug developer Metsera, signaling its return to the weight loss drug market [1] - The GLP-1 market is projected to be substantial, with a potential market size in the hundreds of billions of dollars, prompting multinational corporations (MNCs) to accelerate their investments [1] - Major MNCs such as Novo Nordisk, Eli Lilly, Regeneron, Amgen, Merck, Sanofi, and AbbVie are enhancing their GLP-1 pipelines, indicating strong demand for pipeline development [1] Group 2 - The direction of GLP-1 product development includes multi-targeting, long-acting formulations, oral administration, and weight loss maintenance [1] - Chinese pharmaceutical companies are making comprehensive and differentiated advancements in the GLP-1 sector, showcasing potential for international collaboration [1] - Borui Pharmaceutical has a rich GLP-1 pipeline with significant potential for its product BGM0504, which is progressing well in clinical trials [1] Group 3 - Borui Pharmaceutical confirmed that its overseas market expansion is proceeding normally, with its key weight loss drug BGM0504 injection completing US bridging clinical research [1] - The company plans to refine its Phase III clinical plan based on FDA recommendations and has submitted IND applications for its oral BGM0504 tablet and innovative drug BGM1812 injection for weight loss indications in the US [1]

Market Overview - The Shanghai Composite Index fell by 0.18% on September 23, with five industries experiencing gains, led by the banking and coal sectors, which rose by 1.52% and 1.11% respectively [1] - The social services and retail trade sectors saw the largest declines, down by 3.11% and 2.90% respectively [1] - The pharmaceutical and biotechnology industry also declined by 1.93% [1] Capital Flow Analysis - The main capital outflow from the two markets totaled 996.85 billion yuan, with only three industries seeing net inflows: banking (14.00 billion yuan), construction and decoration (1.69 billion yuan), and coal (399.41 million yuan) [1] - The electronics industry experienced the largest net outflow, totaling 200.43 billion yuan, followed by the computer industry with a net outflow of 166.60 billion yuan [1] Pharmaceutical and Biotechnology Sector - The pharmaceutical and biotechnology sector saw a net outflow of 81.15 billion yuan, with 474 stocks in the sector; 32 stocks rose while 441 fell [2] - The top net inflow stocks in this sector included Amgen Pharmaceuticals-U with a net inflow of 114.11 million yuan, followed by China National Pharmaceutical and Guangsheng Tang with inflows of 74.18 million yuan and 73.03 million yuan respectively [2] - The sector's outflow leaderboard featured WuXi AppTec with a net outflow of 65.79 million yuan, followed by Bory Pharmaceutical and Sunflower with outflows of 56.65 million yuan and 49.46 million yuan respectively [4]